Week of July 2, 2012: GSK Extends Deadline for Tender Offer to Acquire Human Genome Services; Sartorius Opens New Filter, Aseptic-Bag Production Facility in Puerto Rico; and More - Pharmaceutical

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of July 2, 2012: GSK Extends Deadline for Tender Offer to Acquire Human Genome Services; Sartorius Opens New Filter, Aseptic-Bag Production Facility in Puerto Rico; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

GlaxoSmithKline (GSK) has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences (HGS) for $13.00 per share in cash to 5:00 pm EST on July 20, 2012. GSK’s tender offer will expire after July 16, the deadline set by HGS for submission of definitive acquisition proposals in its strategic alternatives review process which began on Apr. 19, 2012, after GSK made a private proposal on Apr. 11. Read More

Merck & Co. and AstraZeneca have agreed to amend their option agreement related to their partnership known as AstraZeneca LP (AZLP), which concerns Merck’s interest in the AstraZeneca gastrointestinal drugs Prilosec (omeprazole) and Nexium (esomeprazole). The updated agreement provides that AstraZeneca will not exercise its option to acquire Merck’s remaining interest in AZLP in 2012, and provides AstraZeneca a new option to acquire Merck’s partnership interest in June 2014. Read More

Sartorius has officially opened its new filter and aseptic-bag production facility for biopharmaceutical applications at its site in Puerto Rico. The company invested approximately EUR 16 million ($20.2 million) into the expansion of its production capacity in Puerto Rico. Covering an area of 5000 m2 (53,820 ft2), the new building complex provides space for two new cleanrooms for filter and bag manufacture, laboratories, and offices. By the end of the 2012, bag-manufacturing operations will be moved from the company’s present site in Concord, California, to Yauco, Puerto Rico. There, Sartorius has added about 120 new employees and thus nearly doubled its workforce at that location. The Concord site is due to close by the end of 2012. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here